TITLE:
Long-Term Persistent Absolute Insulin Secretion Deficiency in Diabetes Induced by Immune Checkpoint Inhibitors
AUTHORS:
Moctar Bah, Clara Bouché, Jean-François Gautier
KEYWORDS:
Immune Checkpoint Inhibitors, Nivolumab, Ipilimumab, Fulminant Diabetes, Insulin-Requiring Diabetes
JOURNAL NAME:
Open Journal of Endocrine and Metabolic Diseases,
Vol.13 No.12,
December
27,
2023
ABSTRACT: Immune checkpoint inhibitors are today an immense hope in the management
of cancers. However, since their widespread use, many cases of
insulin-requiring diabetes appearing suddenly, as fulminant diabetes have been
reported. Here, we describe 4 cases that occurred at different times after the
beginning of immune checkpoint inhibitor therapy with Nivolumab alone or
associated with Ipilimumab. There are 3 cases of newly diagnosed diabetes and 1
case of known type 2 diabetes formerly quite well balanced with Metformin. The
clinical and biological characteristics of these patients are quite similar.
They were all insulin-requiring at the discovery of diabetes and remained so
throughout their follow-up. This type of diabetes which looks like type 1
diabetes seems rather to be a new entity.